The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Combining microenvironment normalization strategies to improve cancer immunotherapy
Open accessAbstract
Significance: Immunotherapy has changed the standard of care in cancer treatment, but an estimated 87% of patients currently do not derive long-term benefit from immune checkpoint blocker monotherapy. Therefore, new therapeutic strategies are needed to improve the response rates in patients who are resistant to immune checkpoint inhibition. We have developed a mathematical framework to determine how tumor microenvironment normalization strategies—specifically, vascular and stroma normalization—might improve immunotherapy efficacy. By incorporating complex interactions among various types of cancer cells, immune cells, stromal cells, and the vasculature, as well as physical mechanisms, we provide guidelines for designing effective combinatorial therapeutic strategies and point out areas for future investigation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527 · cited 11×
“This dose- and time-dependency of vascular normalization results in a “normalization window” within which perfusion is improved (33, 38).”
InfluentialSelf-citationTGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
Mariathasan, S., Turley, S. J., Nickles, D., Castiglioni, A., Yuen, K., Wang, Y., Kadel III, E. E., Koeppen, H., Astarita, J. L., Cubas, R., et al. (2018) · Nature · doi:10.1038/nature25501 · Cited by 5,400 · cited 2×
“In addition, hypoxia and acidity affect the function of T lymphocytes and other immune cells (14 – 16), whereas hypoperfusion and the dense/stiff TME is a physical barrier to T cell infiltration into the tumor (17, 18).”
Elements of cancer immunity and the cancer–immune set point
Chen, D. S., & Mellman, I. (2017) · Nature · doi:10.1038/nature21349 · Cited by 5,352 · cited 8×
“Increased numbers of CD4 + and CD8 + T cells enhances production rates of IFN γ , which is associated with decreased vessel wall pore size and permeability, leading to vascular normalization.”
InfluentialAtezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez-Abreu, D., Moro-Sibilot, D., Thomas, C. A., Barlesi, F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1716948 · Cited by 3,733
Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma
Rini, B. I., Plimack, E. R., Stus, V., Gafanov, R., Hawkins, R., Nosov, D., Pouliot, F., Alekseev, B., Soulières, D., Melichar, B., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816714 · Cited by 3,403
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,180
Self-citationA methodology for performing global uncertainty and sensitivity analysis in systems biology
Marino, S., Hogue, I. B., Ray, C. J., & Kirschner, D. E. (2008) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2008.04.011 · Cited by 2,999
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
Topalian, S. L., Taube, J. M., Anders, R. A., & Pardoll, D. M. (2016) · Nature Reviews Cancer · doi:10.1038/nrc.2016.36 · Cited by 2,733 · cited 1×
“Biomarkers based on the expression of PD-L1, have been proposed only for certain tumor types (63).”
Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma
Motzer, R. J., Penkov, K., Haanen, J., Rini, B., Albiges, L., Campbell, M. T., Venugopal, B., Kollmannsberger, C., Negrier, S., Uemura, M., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1816047 · Cited by 2,503
Transforming Growth Factor-β Signaling in Immunity and Cancer
Batlle, E., & Massagué, J. (2019) · Immunity · doi:10.1016/j.immuni.2019.03.024 · Cited by 2,366
Drug delivery with carbon nanotubes for in vivo cancer treatment
Liu, Z., Chen, K., Davis, C. R., Sherlock, S. P., Cao, Q., Chen, X. S., & Dai, H. (2008) · PubMed · doi:10.48550/arxiv.0808.2070 · Cited by 2,286
Vessel Cooption, Regression, and Growth in Tumors Mediated by Angiopoietins and VEGF
Holash, J., Maisonpierre, P. C., Compton, D., Boland, P., Alexander, C. R., Zagzag, D., Yancopoulos, G. D., & Wiegand, S. J. (1999) · Science · doi:10.1126/science.284.5422.1994 · Cited by 2,195
Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy
Jain, R. K. (2001) · Nature Medicine · doi:10.1038/nm0901-987 · Cited by 2,184
Self-citationNoman, M. Z., Desantis, G., Janji, B., Hasmim, M., Karray, S., Dessen, P., Bronte, V., & Chouaib, S. (2014) · Journal of Experimental Medicine · doi:10.1084/jem.20131916 · Cited by 2,166
Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
Fukumura, D., Kloepper, J., Amoozgar, Z., Duda, D. G., & Jain, R. K. (2018) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2018.29 · Cited by 2,027
Self-citationWillett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., Chung, D. C., Sahani, D. V., Kalva, S. P., Kozin, S. V., et al. (2004) · Nature Medicine · doi:10.1038/nm988 · Cited by 1,966
Self-citationNormalization of the Vasculature for Treatment of Cancer and Other Diseases
Goel, S., Duda, D. G., Xu, L., Munn, L. L., Boucher, Y., Fukumura, D., & Jain, R. K. (2011) · Physiological Reviews · doi:10.1152/physrev.00038.2010 · Cited by 1,605
Self-citationAntiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Jain, R. K. (2014) · Cancer Cell · doi:10.1016/j.ccell.2014.10.006 · Cited by 1,589 · cited 1×
“As a result, perfusion can be increased within the tumor (37).”
Self-citationHaslam, A., & Prasad, V. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2019.2535 · Cited by 1,413 · cited 1×
“While treatment responses are often durable, only a small fraction of patients receiving anti–PD-1/PD-L1 therapy are “cured,” while an estimated 87% of US cancer patients currently do not benefit from ICB monotherapies (5).”
Determinants of tumor blood flow: a review.
Jain, R. K. (1988) · PubMed · Cited by 1,379
Self-citationTumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
Facciabene, A., Peng, X., Hagemann, I. S., Balint, K., Barchetti, A., Wang, L.-P., Gimotty, P. A., Gilks, C. B., Lal, P., Zhang, L., et al. (2011) · Nature · doi:10.1038/nature10169 · Cited by 1,376
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Jain, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.3653 · Cited by 1,248
Self-citationSalmon, H., Franciszkiewicz, K., Damotte, D., Dieu-Nosjean, M.-C., Validire, P., Trautmann, A., Mami-Chouaib, F., & Donnadieu, E. (2012) · Journal of Clinical Investigation · doi:10.1172/jci45817 · Cited by 1,138
Huang, Y., Yuan, J., Righi, E., Kamoun, W. S., Ancukiewicz, M., Nezivar, J., Santosuosso, M., Martin, J. D., Martin, M. R., Vianello, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1215397109 · Cited by 1,099 · cited 5×
“The sole model parameter that was adjusted to fit the experimental data (19, 24, 26, 36, 49) was k1, which describes the dependence of cancer cell proliferation on oxygen concentration (SI Appendix, Table S2).”
InfluentialSelf-citationChauhan, V. P., Martin, J. D., Liu, H., Lacorre, D. A., Jain, S. R., Kozin, S. V., Stylianopoulos, T., Mousa, A. S., Han, X., Adstamongkonkul, P., et al. (2013) · Nature Communications · doi:10.1038/ncomms3516 · Cited by 1,031 · cited 1×
“We have referred to this approach as stroma normalization (27 – 30).”
Self-citationTumor Induction of VEGF Promoter Activity in Stromal Cells
Fukumura, D., Xavier, R., Sugiura, T., Chen, Y., Park, E.-C., Lu, N., Selig, M., Nielsen, G., Taksir, T., Jain, R. K., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81731-6 · Cited by 996
Self-citationCauses, consequences, and remedies for growth-induced solid stress in murine and human tumors
Stylianopoulos, T., Martin, J. D., Chauhan, V. P., Jain, S. R., Diop-Frimpong, B., Bardeesy, N., Smith, B. L., Ferrone, C. R., Hornicek, F. J., Boucher, Y., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1213353109 · Cited by 943
Self-citationFukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.19.03296 · Cited by 890
Cancer cells compress intratumour vessels
Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., Tomaso, E. D., & Jain, R. K. (2004) · Nature · doi:10.1038/427695a · Cited by 857
Self-citationMutual regulation of tumour vessel normalization and immunostimulatory reprogramming
Tian, L., Goldstein, A., Wang, H., Ching Lo, H., Sun Kim, I., Welte, T., Sheng, K., Dobrolecki, L. E., Zhang, X., Putluri, N., et al. (2017) · Nature · doi:10.1038/nature21724 · Cited by 841 · cited 2×
“According to previous experimental findings, IFNγ concentration affects vessel permeability; specifically, elimination of immune CD4 T cells and CD8 T cells leads to a decrease in IFNγ, which in turn increases vessel wall pore size and vessel permeability by fivefold (42, 76).”
EGFR-TKI resistance due to BIM polymorphism can be circumvented in combination with HDAC inhibition
中川, 学. (2014) · Institutional Repositories DataBase (IRDB) · Cited by 736
Quezada, S. A. (2006) · Journal of Clinical Investigation · doi:10.1172/jci27745 · Cited by 700 · cited 1×
“In addition, anti–PD-1 treatment was modeled as an increase in CD8 T cells, and anti–CTLA-4 treatment was modeled as a decrease in regulatory T cells (Tregs), in line with the reported effects of these two treatments (50).”
Rolny, C., Mazzone, M., Tugues, S., Laoui, D., Johansson, I., Coulon, C., Squadrito, M. L., Segura, I., Li, X., Knevels, E., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2010.11.009 · Cited by 695 · cited 4×
“According to previous studies TAMs are associated with VEGF expression (25, 30, 31).”
InfluentialTransport of Molecules, Particles, and Cells in Solid Tumors
Jain, R. K. (1999) · Annual Review of Biomedical Engineering · doi:10.1146/annurev.bioeng.1.1.241 · Cited by 691
Self-citationImproving cancer immunotherapy using nanomedicines: progress, opportunities and challenges
Martin, J. D., Cabral, H., Stylianopoulos, T., & Jain, R. K. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0308-z · Cited by 682
Self-citationLobov, I. B., Brooks, P. C., & Lang, R. A. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172161899 · Cited by 676 · cited 1×
“…by pericytes, while Ang2 is produced mainly by endothelial cells, and the two have competing effects: Ang1 and PDGF-β have been shown to stabilize endothelial cells, producing mature vessels, while Ang2 has the opposite effect, destabilizing endothelial cells, favoring angiogenesis (77, 78).”
Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
Huang, Y., Goel, S., Duda, D. G., Fukumura, D., & Jain, R. K. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4354 · Cited by 669
Self-citationAntiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia
Conley, S. J., Gheordunescu, E., Kakarala, P., Newman, B., Korkaya, H., Heath, A. N., Clouthier, S. G., & Wicha, M. S. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018866109 · Cited by 663
A Validated Mathematical Model of Cell-Mediated Immune Response to Tumor Growth
de Pillis, L. G., Radunskaya, A. E., & Wiseman, C. L. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0564 · Cited by 649
Calcinotto, A., Filipazzi, P., Grioni, M., Iero, M., De Milito, A., Ricupito, A., Cova, A., Canese, R., Jachetti, E., Rossetti, M., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-1272 · Cited by 640
A review on CXCR4/CXCL12 axis in oncology: No place to hide
Domanska, U. M., Kruizinga, R. C., Nagengast, W. B., Timmer-Bosscha, H., Huls, G., de Vries, E. G. E., & Walenkamp, A. M. E. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2012.05.005 · Cited by 635
Stylianopoulos, T., Munn, L. L., & Jain, R. K. (2018) · Trends in Cancer · doi:10.1016/j.trecan.2018.02.005 · Cited by 563
Self-citationRole of Angiopoietin-2 in Vascular Physiology and Pathophysiology
Akwii, R. G., Sajib, M. S., Zahra, F. T., & Mikelis, C. M. (2019) · Cells · doi:10.3390/cells8050471 · Cited by 543
Normalizing Function of Tumor Vessels: Progress, Opportunities, and Challenges
Martin, J. D., Seano, G., & Jain, R. K. (2019) · Annual Review of Physiology · doi:10.1146/annurev-physiol-020518-114700 · Cited by 530
Self-citationCombining two strategies to improve perfusion and drug delivery in solid tumors
Stylianopoulos, T., & Jain, R. K. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318415110 · Cited by 508 · cited 2×
“Stroma normalization is beneficial in desmoplastic tumors with abundant compressed vessels, whereas vascular normalization should improve perfusion in tumors with hyperpermeable vessels with open lumens (20).”
Makker, V., Rasco, D., Vogelzang, N. J., Brose, M. S., Cohn, A. L., Mier, J., Di Simone, C., Hyman, D. M., Stepan, D. E., Dutcus, C. E., et al. (2019) · The Lancet Oncology · doi:10.1016/s1470-2045(19)30020-8 · Cited by 476 · cited 1×
“Also, the effect of lenvatinib plus pembrolizumab is being investigated in a randomized phase III clinical study, as it was found that this treatment had antitumor activity in patients with advanced recurrent endometrial cancer (59).”
Chen, Y., Ramjiawan, R. R., Reiberger, T., Ng, M. R., Hato, T., Huang, Y., Ochiai, H., Kitahara, S., Unan, E. C., Reddy, T. P., et al. (2015) · Hepatology · doi:10.1002/hep.27665 · Cited by 451
Self-citationShigeta, K., Datta, M., Hato, T., Kitahara, S., Chen, I. X., Matsui, A., Kikuchi, H., Mamessier, E., Aoki, S., Ramjiawan, R. R., et al. (2020) · Hepatology · doi:10.1002/hep.30889 · Cited by 409
Self-citationChen, I. X., Chauhan, V. P., Posada, J., Ng, M. R., Wu, M. W., Adstamongkonkul, P., Huang, P., Lindeman, N., Langer, R., & Jain, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1815515116 · Cited by 406 · cited 6×
“24 and 26), stroma normalization was applied to improve perfusion and enhance the efficacy of ICBs (anti – PD-1 and anti – CTLA-4) in murine breast tumors.”
InfluentialSelf-citationTheory of oxygen transport to tissue.
Popel, A. S. (1989) · PubMed · Cited by 406
Noman, M. Z., Hasmim, M., Messai, Y., Terry, S., Kieda, C., Janji, B., & Chouaib, S. (2015) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00207.2015 · Cited by 400
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
Sharma, A., Subudhi, S. K., Blando, J., Scutti, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-0762 · Cited by 382 · cited 1×
“In addition, a clinical study found that anti – CTLA-4 immunotherapy does not deplete regulatory T cells (64).”
Kloepper, J., Riedemann, L., Amoozgar, Z., Seano, G., Susek, K., Yu, V., Dalvie, N., Amelung, R. L., Datta, M., Song, J. W., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525360113 · Cited by 357
Self-citation(1999) · PubMed · Cited by 348
Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy
Pinter, M., & Jain, R. K. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aan5616 · Cited by 332
Self-citationPeterson, T. E., Kirkpatrick, N. D., Huang, Y., Farrar, C. T., Marijt, K. A., Kloepper, J., Datta, M., Amoozgar, Z., Seano, G., Jung, K., et al. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1525349113 · Cited by 317
Self-citationSharma, A., Subudhi, S. K., Blando, J., Vence, L., Wargo, J., Allison, J. P., Ribas, A., & Sharma, P. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0402 · Cited by 312
Immuno-oncology drug development goes global
Xin Yu, J., Hubbard-Lucey, V. M., & Tang, J. (2019) · Nature Reviews Drug Discovery · doi:10.1038/d41573-019-00167-9 · Cited by 260
Zhao, Y., Cao, J., Melamed, A., Worley, M., Gockley, A., Jones, D., Nia, H. T., Zhang, Y., Stylianopoulos, T., Kumar, A. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818357116 · Cited by 259
Self-citationIncreased vessel perfusion predicts the efficacy of immune checkpoint blockade
Zheng, X., Fang, Z., Liu, X., Deng, S., Zhou, P., Wang, X., Zhang, C., Yin, R., Hu, H., Chen, X., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci96582 · Cited by 239
Hayakawa, Y., Takeda, K., Yagita∥, H., Smyth, M. J., Kaer, L. V., Okumura, K., & Saiki, I. (2002) · PubMed · Cited by 220
Molecular pathways: hypoxia response in immune cells fighting or promoting cancer
Palazón, A., Aragonés, J., Morales-Kastresana, A., de Landázuri, M. O., & Melero, I. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-1591 · Cited by 214
Chauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 206
Self-citationAngiopoietin–Tie signalling in the cardiovascular and lymphatic systems
Eklund, L., Kangas, J., & Saharinen, P. (2017) · Clinical Science · doi:10.1042/cs20160129 · Cited by 202
Vascular regulation of antitumor immunity
Munn, L. L., & Jain, R. K. (2019) · Science · doi:10.1126/science.aaw7875 · Cited by 195
Self-citationGordon-Alonso, M., Hirsch, T., Wildmann, C., & van der Bruggen, P. (2017) · Nature Communications · doi:10.1038/s41467-017-00925-6 · Cited by 186
Pirfenidone normalizes the tumor microenvironment to improve chemotherapy
Polydorou, C., Mpekris, F., Papageorgis, P., Voutouri, C., & Stylianopoulos, T. (2017) · Oncotarget · doi:10.18632/oncotarget.15534 · Cited by 185
Self-citationDatta, M., Coussens, L. M., Nishikawa, H., Hodi, F. S., & Jain, R. K. (2019) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_237987 · Cited by 184
Self-citationRole of vascular normalization in benefit from metronomic chemotherapy
Mpekris, F., Baish, J. W., Stylianopoulos, T., & Jain, R. K. (2017) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1700340114 · Cited by 178 · cited 5×
“The proliferation rate of CCs increases with increasing oxygen level, while the proliferation rates of CSCs and ICCs increase under hypoxic conditions (41, 74).”
InfluentialSelf-citationMathematical modeling of tumor-immune cell interactions
Mahlbacher, G. E., Reihmer, K. C., & Frieboes, H. B. (2019) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2019.03.002 · Cited by 166
Papageorgis, P., Polydorou, C., Mpekris, F., Voutouri, C., Agathokleous, E. A., Kapnissi‐Christodoulou, C. P., & Stylianopoulos, T. (2017) · Scientific Reports · doi:10.1038/srep46140 · Cited by 148
Self-citationMartin, J. D., Panagi, M., Wang, C., Khan, T., Martin, M. R., Voutouri, C., Toh, K., Papageorgis, P., Mpekris, F., Polydorou, C., et al. (2019) · ACS Nano · doi:10.1021/acsnano.8b07865 · Cited by 144
Self-citationBoige, V., Malka, D., Bourredjem, A., Dromain, C., Baey, C., Jacques, N., Pignon, J., Vimond, N., Bouvet-Forteau, N., de Baère, T., et al. (2012) · The Oncologist · doi:10.1634/theoncologist.2011-0465 · Cited by 135
Mpekris, F., Angeli, S. I., Pirentis, A. P., & Stylianopoulos, T. (2015) · Biomechanics and Modeling in Mechanobiology · doi:10.1007/s10237-015-0682-0 · Cited by 123
Self-citationMathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment
Mahlbacher, G. E., Curtis, L. T., Lowengrub, J. S., & Frieboes, H. B. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-017-0313-7 · Cited by 112
Voutouri, C., Kirkpatrick, N. D., Chung, E., Mpekris, F., Baish, J. W., Munn, L. L., Fukumura, D., Stylianopoulos, T., & Jain, R. K. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1818322116 · Cited by 111
Self-citationMpekris, F., Papageorgis, P., Polydorou, C., Voutouri, C., Kalli, M., Pirentis, A. P., & Stylianopoulos, T. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.06.022 · Cited by 107
Self-citationMilberg, O., Gong, C., Jafarnejad, M., Bartelink, I. H., Wang, B., Vicini, P., Narwal, R., Roskos, L. K., & Popel, A. S. (2019) · Scientific Reports · doi:10.1038/s41598-019-47802-4 · Cited by 98
Emerging predictors of the response to the blockade of immune checkpoints in cancer therapy
Li, X., Song, W., Shao, C., Shi, Y., & Han, W. (2018) · Cellular and Molecular Immunology · doi:10.1038/s41423-018-0086-z · Cited by 81
Regan, D. P., Coy, J. W., Chahal, K. K., Chow, L., Kurihara, J. N., Guth, A., Kufareva, I., & DOW, S. W. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1800619 · Cited by 79
Wang, H., Milberg, O., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L. K., Santa-Maria, C. A., & Popel, A. S. (2019) · Royal Society Open Science · doi:10.1098/rsos.190366 · Cited by 69
Fukuoka, S., Hara, H., Takahashi, N., Kojima, T., Kawazoe, A., Asayama, M., Yoshii, T., Kotani, D., Tamura, H., Mikamoto, Y., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.2522 · Cited by 69
A Computational Model of Neoadjuvant PD-1 Inhibition in Non-Small Cell Lung Cancer
Jafarnejad, M., Gong, C., Gabrielson, E., Bartelink, I. H., Vicini, P., Wang, B., Narwal, R., Roskos, L. K., & Popel, A. S. (2019) · The AAPS Journal · doi:10.1208/s12248-019-0350-x · Cited by 66
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy
Xie, G., Tan, C., Lin, J., Zhang, L., Zheng, J., Liu, Y., Xie, G., Wang, B., & Yuan, Y. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0401-3 · Cited by 65
CD4 + T Cell Activation and Vascular Normalization: Two Sides of the Same Coin?
Palma, M. D., & Jain, R. K. (2017) · Immunity · doi:10.1016/j.immuni.2017.04.015 · Cited by 54
Self-citationGoel, S., Fukumura, D., & Jain, R. K. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1203794109 · Cited by 44
Self-citationPharmacokinetics of methotrexate in solid tumors
Jain, R. K., Wei, J., & Gullino, P. M. (1979) · Journal of Pharmacokinetics and Biopharmaceutics · doi:10.1007/bf01059737 · Cited by 37
Self-citationThe role of receptor MAS in microglia-driven retinal vascular development
Foulquier, S., Caolo, V., Swennen, G., Milanova, I. V., Reinhold, S., Recarti, C., Alenina, N. V., Bäder, M., Steckelings, U. M., Vanmierlo, T., et al. (2019) · Angiogenesis · doi:10.1007/s10456-019-09671-3 · Cited by 31
Cited by
Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Pyroptosis: a new paradigm of cell death for fighting against cancer
Tan, Y., Chen, Q., Li, X., Zeng, Z., Xiong, W., Li, G., Li, X., Yang, J., Xiang, B., & Yi, M. (2021) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-021-01959-x · Cited by 467
Neophytou, C. M., Panagi, M., Stylianopoulos, T., & Papageorgis, P. (2021) · Cancers · doi:10.3390/cancers13092053 · Cited by 456
Self-citationThe Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Pinter, M., Jain, R. K., & Duda, D. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 339
Self-citation
Metadata
- Authors
- Mpekris, F., Voutouri, C., Baish, J. W., Duda, D. G., Munn, L. L., Stylianopoulos, T., & Jain, R. K.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2020-02-03
- Volume
- 117
- Issue
- 7
- Pages
- 3728-3737
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W3003714437
- Cited by
- 286
- References
- 88
- FWCI
- 6.14
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.